HMGB1在冠心病炎症反应及易损斑块中作用的初探

新发传染病电子杂志 ›› 2017, Vol. 2 ›› Issue (3): 179-182.

HMGB1在冠心病炎症反应及易损斑块中作用的初探

胡亚男¹, 杜少辉², 陈思诺^1,3, 胡天祥⁴

1.深圳市龙岗区人民医院,深圳,518100;
2.深圳市中医院老年病科,深圳 518000;
3.深圳市龙岗区中医院,深圳 518100;
4.广东省中医院,广州 510120

收稿日期:2017-07-01 出版日期:2017-08-31 发布日期:2020-07-13
通讯作者: 杜少辉,Email:674663653@qq.com
基金资助:
国家自然科学基金面上项目（81173377）

The role of HMGB1 in inflammatory response and vulnerable plaque in coronary heart disease

HU Ya-nan¹, DU Shao-hui², CHEN Si-nuo^1,3, HU Tian-xiang⁴

1. Shenzhen Longgang People's Hospital, Guangdong Shenzhen 518100,China;
2. Shenzhen Chinese Traditional Medical Hospital,Guangdong Shenzhen 518000,China;
3. Shenzhen Longgang Hospital of Tradition Chinese Medicine, Guangdong Shenzhen 518100,China;
4. Guangdong Province Traditional Chinese Medical Hospital, Guangzhou 510120, China

Received:2017-07-01 Online:2017-08-31 Published:2020-07-13

摘要/Abstract

摘要： 目的探讨冠心病患者血清高迁移率族蛋白B1(high mobility group box protein 1,HMGB1）、基质金属蛋白酶-9的水平与冠心病炎症反应及冠状动脉粥样斑块稳定性之间的关系。方法选择2013年8月至2014年1月收住广东省中医院大学城分院的冠心病患者58例,选择同期住院冠脉造影显示血管正常者30例作为对照。均于患者冠脉造影术中未给予肝素前抽取患者3ml动脉血于试管内,集中采用ELISA法检测血清中HMGB1与MMP-9的浓度。结果 ①血清HMGB1水平在稳定性心绞痛组(SA)、不稳定性心绞痛组(UA)、急性心梗组(AMI)依次增高,各组间差异显著(P<0.05),且明显高于正常对照组(NC)(P<0.05);②CHD组患者血清MMP-9水平显著升高,与正常对照组比较差异有统计学意义（P<0.05）;③冠心病患者血清HMGB1与MMP-9行Pearson相关性分析发现,血清HMGB1与MMP-9呈显著正相关(P<0.01);结论 HMGB1与临床常规检测的炎症、血脂等指标有一定的相关性,可推断HMGB1为CHD分型的独立相关因素,并可间接反映斑块内炎症的活跃程度,且HMGB1与MMP-9呈显著正相关,推测检测HMGB1可在一定程度上预测斑块稳定性,可为冠心病的抗炎治疗提供依据。

关键词: 冠状动脉粥样硬化性心脏病, 炎症反应, 高迁移率蛋白B1, 基质金属蛋白酶-9

Abstract: Objective To study the relationship between the levels of HMGB1, MMP-9, and the stability of coronary artery atheromatous plaque, to further discover the relationship among immune response, inflammatory reaction and coronary heart disease.Method Fifty-eight coronary heart disease patients who were cured between - August 2013 to January 2014 in Guangdong Province Hospital Of Traditional Chinese Medicine were enrolled. Thirty healthy individuals who were cured during the same time in our hospital without structural heart disease (but with normal heart function) were enrolled as control group. ELISA kit was used to detect the HMGB1, MMP-9, concentration of stored examples.Result i) Serum HMGB1 level was gradually increased in the control groups, considering the SA, UA and AMI groups, and it indicated a significant statistic difference(P<0.05); and is higher than the controls. ii) Serum level of MMP-9 was significantly higher in coronary heart disease groups than the control group, and it indicated a significant statistic difference(P<0.05). iii) Serum levels of HMGB1、MMP-9 were also significantly different, HMGB1 and MMP-9 levels correlated positively (r=0.463 P<0.05).Conclusion HMGB1 has certain correlation with clinical routine detection of inflammation, blood lipid and other indicators, it could be inferred that HMGB1 was an independent factor of CHD classification, and could indirectly reflect the degree of active inflammation in plaque. HMGB1 was also positively correlated with MMP-9, suggesting that the detection of HMGB1 could predict plaque stability to a certain extent and provide a reliable basis for the anti-inflammatory treatment of coronary heart disease.

Key words: Coronary heart disease, Inflammatory, High mobility group box protein 1, Matrix metallo proteinase-9

胡亚男, 杜少辉, 陈思诺, 胡天祥. HMGB1在冠心病炎症反应及易损斑块中作用的初探[J]. 新发传染病电子杂志, 2017, 2(3): 179-182.

HU Ya-nan, DU Shao-hui, CHEN Si-nuo, HU Tian-xiang. The role of HMGB1 in inflammatory response and vulnerable plaque in coronary heart disease[J]. Electronic Journal of Emerging Infectious Diseases, 2017, 2(3): 179-182.

参考文献

[1] Goodwin G H, Johns E W.Isolation and characterization of two cal-f thymus chro-matinnon-histoneproteins with high ontents of acidic and basic amino acids[J]. Eur JBiochem, 1973, 40(1): 215-219.
[2] Eriksson E E, Xie X, Werr J, et al.Importance of primary capture and L-selectin-dependent secondary capture in leukocyte accumulation in inflammation and atherosclerosis in vivo[J]. J Exp Med, 2001, 194(2): 205-218.
[3] Stemme S, Faber B, Holm J, et al.T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein[J]. Proc Natl Acad Sci U S A, 1995, 92(9): 3893-3897.
[4] Madhur M S, Funt S A, Li L, et al.Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice[J]. Arterioscler Thromb Vasc Biol, 2011, 31(7): 1565-1572.
[5] Ross R.The pathogenesis of atherosclerosis--an update[J]. N Engl J Med, 1986, 314(8): 488-500.
[6] Peter Libby.Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy .N Engl [J] Med.2013.368; 2004-2013.
[7] Hansson G K, Hellstrand M, Rymo L, et al.Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells[J]. J Exp Med, 1989, 170(5): 1595-1608.
[8] Amento E P, Ehsani N, Palmer H, et al.Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells[J]. Arterioscler Thromb, 1991, 11(5): 1223-1230.
[9] Jin DQ,Wu YB, Zhao L et al. Atorvastatin reduces serum HMGBl levels in patients with hyperlipidemia[J], Exp Ther Med,2012,4(l): 1124-1126.
[10] Kalinina N, Agrotis A, Antropova Y, et al.Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines[J]. Arterioscler Thromb Vasc Biol, 2004, 24(12): 2320-2325.
[11] Porto A, Palumbo R, Pieroni M, et al.Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein[J]. FASEB J, 2006, 20(14): 2565-2566.
[12] de Souza A W, Westra J, Limburg P C, et al. HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis[J]. Autoimmun Rev, 2012, 11(12): 909-917.
[13] Inoue K, Kawahara K, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M,et al.HMGBl expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques[J], Cardiovasc Patho 2007;16(2): 136-143.
[14] Monroe V S, Kerensky R A, Rivera E, et al.Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes[J]. J Am Coll Cardiol, 2003, 41(4 Suppl S): 23S-30S.
[15] Dodd T, Jadhav R, Wiggins L, et al.MMPs 2 and 9 are essential for coronary collateral growth and are prominently regulated by p38 MAPK[J]. J Mol Cell Cardiol, 2011, 51(6): 1015-1025.
[16] Brown D L, Hibbs M S, Kearney M, et al.Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina[J]. Circulation, 1995, 91(8): 2125-2131.
[17] 史恒川,刘俊恒,朱建一.老年冠心病患者血清白细胞介素6及高迁移率蛋白B1水平的观察[J].实用老年医学,2011,25(5);412-414.